Zeynettin Kaya, Fuat Polat, Ufuk İyigün, Cuma Süleymanoğlu, Gamze Yeter Arslan, İsmail Ateş
{"title":"Efficacy and Safety of TriClip Procedure in Patients with Severe Tricuspid Regurgitation and Large Coaptation Gap.","authors":"Zeynettin Kaya, Fuat Polat, Ufuk İyigün, Cuma Süleymanoğlu, Gamze Yeter Arslan, İsmail Ateş","doi":"10.1007/s10557-025-07775-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the safety and efficacy of transcatheter tricuspid valve repair using the TriClip system in patients with severe tricuspid regurgitation (TR) and large coaptation gaps (> 10 mm), a subgroup traditionally considered anatomically challenging for edge-to-edge repair.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 9 symptomatic patients who underwent TriClip implantation at multiple centers in Turkey between March 2024 and May 2025. All patients had severe or greater TR with coaptation gaps exceeding 10 mm and were deemed high-risk for surgical intervention. Clinical and echocardiographic parameters were collected before and after the procedure.</p><p><strong>Results: </strong>The mean age of patients was 68.4 ± 8.6 years. The average coaptation gap was 17.56 ± 3.43 mm. The procedure achieved 100% technical success, defined as at least a one-grade reduction in TR severity. The mean number of clips implanted was 3.22 ± 0.83, with the XTW clip used in 86.3% of cases. No major complications or in-hospital mortality occurred. Symptomatic improvement was observed in all patients, with most experiencing at least one New York Heart Association (NYHA) class reduction. Mean follow-up duration was 6.7 ± 2.4 months.</p><p><strong>Conclusion: </strong>TriClip repair appears to be a safe and effective therapeutic option in high-risk patients with severe TR and large coaptation gaps. Despite anatomical complexity, significant reductions in TR severity and clinical symptoms were achieved, with low complication rates. These findings support the feasibility of TriClip therapy in this challenging patient population.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07775-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study aimed to evaluate the safety and efficacy of transcatheter tricuspid valve repair using the TriClip system in patients with severe tricuspid regurgitation (TR) and large coaptation gaps (> 10 mm), a subgroup traditionally considered anatomically challenging for edge-to-edge repair.
Methods: A retrospective analysis was conducted on 9 symptomatic patients who underwent TriClip implantation at multiple centers in Turkey between March 2024 and May 2025. All patients had severe or greater TR with coaptation gaps exceeding 10 mm and were deemed high-risk for surgical intervention. Clinical and echocardiographic parameters were collected before and after the procedure.
Results: The mean age of patients was 68.4 ± 8.6 years. The average coaptation gap was 17.56 ± 3.43 mm. The procedure achieved 100% technical success, defined as at least a one-grade reduction in TR severity. The mean number of clips implanted was 3.22 ± 0.83, with the XTW clip used in 86.3% of cases. No major complications or in-hospital mortality occurred. Symptomatic improvement was observed in all patients, with most experiencing at least one New York Heart Association (NYHA) class reduction. Mean follow-up duration was 6.7 ± 2.4 months.
Conclusion: TriClip repair appears to be a safe and effective therapeutic option in high-risk patients with severe TR and large coaptation gaps. Despite anatomical complexity, significant reductions in TR severity and clinical symptoms were achieved, with low complication rates. These findings support the feasibility of TriClip therapy in this challenging patient population.
期刊介绍：
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
